IL17A and psoriasis: By using psoriasis mouse models, induced by imiquimod (IMQ) and IL-23, Danay Cibrian found that targeting LAT1-mediated amino acid uptake is a potentially useful immunosuppressive strategy to control skin inflammation mediated by the IL-23/IL-1β/IL-17 axis [36].